メタボリックシンドローム患者における水素リッチサンゴカルシウムカプセルの安全性と脂質低下効果の検討：前向き症例シリーズ研究
A prospective case series enrolled 16 Taiwanese patients with metabolic syndrome (7 male, 9 female; mean age 62 years; range 32–80) who were assigned to low, medium, or high doses of hydrogen-rich coral calcium (HRCC) capsules for 4 weeks. The primary endpoint was the occurrence of adverse effects, while secondary endpoints included changes in lipid profiles, complete blood count, inflammatory biomarkers, and quality of life (QOL). No notable adverse events were documented. Among lipid parameters, only serum triglycerides showed a statistically significant reduction, declining from a baseline mean of 193.19 μL (SD 107.44) to 151.75 μL (SD 45.27) after the 4-week course (p = 0.04). QOL scores did not change significantly. The authors conclude that short-term HRCC use appears safe and may confer triglyceride-lowering effects, supporting the rationale for longer-duration clinical investigations.
Molecular hydrogen delivered via coral calcium capsules is proposed to exert antioxidant and anti-inflammatory effects following oral ingestion, potentially modulating lipid metabolism and contributing to reductions in circulating triglyceride levels.
Hydrogen-rich water is a low-risk delivery route, but the achievable systemic hydrogen dose is bounded. For clinical applications, inhalation is the most efficient route; inhalation, however, carries explosion risk, and concentration matters (empirical LFL of 10% applies to inhalation environments; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/37521410